I think that Professor Herder outlined some of the steps that Health Canada or Canada has already taken in terms of data protection to try to ensure that the information is not used for unfair commercial purposes. In terms of the full results of the clinical trials that have been undertaken, we could initially look at what I described with respect to the model that GlaxoSmithKline has committed to, which is that they will release all of the data on critical trials once researchers have made an application and that application has been vetted by an independent committee so that you get this information out there to the people who will be able to use it.
For instance, ISMP may be interested in that information in terms of developing strategies for better patient protection. CADTH, which evaluates new drugs and technologies, may be interested in that information so that it can write its reports. Other groups in Canada that develop guidelines for clinical practitioners may be interested in that information so that they can include all of the relevant information when they make their recommendations to doctors around how to prescribe drugs most appropriately.